Trials / Unknown
UnknownNCT05185544
Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Neoadjuvant pemetrexed and cisplatin chemotherapy | neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2022-01-11
- Last updated
- 2022-01-11
Source: ClinicalTrials.gov record NCT05185544. Inclusion in this directory is not an endorsement.